UPD LEA Glen Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: UPD LEA Glen Pharmaceutical Import Records from India — 2 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

UPD LEA Glen — Pharmaceutical Importer Profile (2026) | 2 Products, $1.3M Trade | TransData Nexus

UPD LEA Glen

Pharmaceutical Importer · South Africa · Tuberculosis Medications Focus · $1.3M Total Trade · DGFT Verified

UPD LEA Glen is a pharmaceutical importer based in South Africa with a total trade value of $1.3M across 2 products in 1 therapeutic categories. Based on 26 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. UPD LEA Glen sources from 10 verified Indian suppliers, with Lupin Limited accounting for 67.5% of imports.

UPD LEA Glen — Import Portfolio & Supplier Network

UPD LEA Glen import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to UPD LEA Glen?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$13.8M	375	67.5%
Intas Pharmaceuticals Limited	$5.0M	324	24.4%
Strides Pharma Science Limited	$750.0K

What Formulations Does UPD LEA Glen Import?

Formulation	Value	Ships
Betadexamine tablets betamethasone and	$700.0K	14
4 fdc - risopet 84t (south africa)	$400.0K	8
Fripnit plus 3 x 12t rifapentine 300 MG and isoniazid 300 MG	$286.1K	6
4 fdc - risopet 56t (south africa)	$250.0K	5
4 fdc - risopet 84t (south africa) rifampin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets USP	$231.1K	5
4 fdc risopet 56t south africa rifampin 150MG isoniazid 75MG pyrazinamide 400MG and ethambutol hydrochloride 275MG	$224.4K	5
Cef. prox. oral sus. 40MG/5ML-100ML	$214.6K	5
Pharma drugs & medi sedalpha 100mcg/ML	$200.0K	4
Zartan 100 MG (act. qty. 66110.000 ea	$200.0K	4
Zartan 100 MG (act. qty. 65950.000 ea x3x 10t) losartan potassium tablets 100 MG (losartan)	$194.1K	4
4 fdc - risopet 112t (south africa)	$186.3K	4
4 fdc - risopet 56t (south africa) rifampin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets USP	$172.2K	4
Bilocor co(10.0/6.25MG)3x10t	$172.1K	8
Liso unicorn 20MG 30s sa (qty. 14	$153.8K	4
Lisoretic 10, 12.5 MG (act. qty.	$151.3K	4

UPD LEA Glen imports 431 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ethambutol	Tuberculosis Medications	$650.0K	13	0.1%	18
2	Pyrazinamide	Tuberculosis Medications	$650.0K	13	0.1%	12

UPD LEA Glen imports 2 pharmaceutical products across 1 categories into South Africa totaling $1.3M.

UPD LEA Glen — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

UPD Lea Glen, officially known as United Pharmaceutical Distributors (UPD), is a prominent pharmaceutical wholesaler and distributor based in Roodepoort, Gauteng, South Africa. Established over 40 years ago, UPD has played a pivotal role in the South African healthcare sector, ensuring the efficient distribution of pharmaceutical products nationwide. The company's headquarters are located at 14 Tamar Avenue, Lea Glen, Roodepoort, 1709, South Africa. (ivote.co.za)

As a subsidiary of Clicks Group Limited, a leading retail and wholesale group in South Africa, UPD operates as the group's primary pharmaceutical wholesaler. This strategic positioning enables UPD to leverage Clicks Group's extensive retail network, facilitating the widespread distribution of pharmaceutical products across the country. UPD's role encompasses the procurement, storage, and distribution of a vast array of pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced from both local and international manufacturers.

2Distribution Network

UPD's distribution network is centralized at its Lea Glen facility in Roodepoort, which serves as the main warehouse and operational hub. The facility is strategically located to optimize logistics and distribution efficiency across South Africa. While specific details about additional warehouse locations are not publicly disclosed, UPD's extensive distribution capabilities are supported by Clicks Group's retail infrastructure, which includes numerous pharmacies and clinics nationwide. This integrated network ensures timely and reliable delivery of pharmaceutical products to various healthcare providers and retail outlets across the country.

3Industry Role

In South Africa's pharmaceutical supply chain, UPD functions primarily as a wholesaler and distributor. The company is responsible for sourcing pharmaceutical products from manufacturers, both local and international, and distributing them to a wide range of clients, including retail pharmacies, hospitals, clinics, and other healthcare facilities. UPD's role is crucial in bridging the gap between pharmaceutical manufacturers and end-users, ensuring the availability and accessibility of essential medicines throughout the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — UPD LEA Glen

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

UPD's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, UPD imported finished pharmaceutical formulations valued at approximately $1.3 million USD from India, encompassing 26 shipments and 431 unique formulations. The top five products imported were Ethambutol and Pyrazinamide, each accounting for $650,000 USD, representing 0.1% of the total import value. This concentration indicates a strategic choice to source specific medications from Indian manufacturers, likely due to competitive pricing and product availability.

The shipment data reveals a stable relationship between UPD and its Indian suppliers, with Lupin Limited and Intas Pharmaceuticals Limited being the primary suppliers, accounting for 67.5% and 24.4% of the total import value, respectively. This consistent sourcing pattern suggests a reliable and ongoing partnership, reducing the risk associated with supplier dependency. However, the lack of diversification in sourcing could pose challenges if there are disruptions in the Indian pharmaceutical market or changes in regulatory policies affecting imports.

2Supply Chain Resilience

UPD's supply chain resilience is closely tied to its sourcing strategy from India. The company's reliance on a limited number of suppliers for specific formulations indicates a focused procurement approach. While this can lead to favorable pricing and streamlined logistics, it also means that any disruptions in the Indian pharmaceutical industry—such as regulatory changes, manufacturing issues, or geopolitical tensions—could impact UPD's ability to maintain a consistent supply of these critical medications.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African pharmaceutical industry is regulated by the South African Health Products Regulatory Authority (SAHPRA), which operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965). SAHPRA is responsible for the registration, regulation, and control of medicines, medical devices, and related substances to ensure their safety, efficacy, and quality. In August 2020, SAHPRA was granted the authority to manufacture active pharmaceutical ingredients (APIs) for human medicine, marking a significant development in the country's pharmaceutical manufacturing capabilities. (idc.co.za)

Key legislation governing pharmaceutical imports includes the Medicines and Related Substances Act, which outlines the requirements for the importation, registration, and distribution of medicines. The Pharmacy Act, 1974 (Act No. 53 of 1974), also plays a role in regulating the practice of pharmacy and the distribution of pharmaceutical products. These legislative frameworks ensure that all pharmaceutical products entering the South African market meet stringent safety and quality standards.

2Import Licensing & GMP

Pharmaceutical manufacturers and wholesalers in South Africa must obtain licenses from SAHPRA to import and distribute medicines. These licenses are contingent upon compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP), which are essential for maintaining product quality and safety. Additionally, a pharmaceutical manufacturer or wholesaler must be licensed and recorded as a manufacturing or wholesale pharmacy with the South African Pharmacy Council and must further be recorded as a pharmacy owner.

UPD LEA Glen — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

UPD's product strategy focuses on the importation of specific pharmaceutical formulations, particularly those used in the treatment of tuberculosis (TB). Between 2022 and 2026, UPD imported finished pharmaceutical formulations valued at approximately $1.3 million USD from India, encompassing 26 shipments and 431 unique formulations. The top five products imported were Ethambutol and Pyrazinamide, each accounting for $650,000 USD, representing 0.1% of the total import value. This concentration indicates a strategic choice to source specific medications from Indian manufacturers, likely due to competitive pricing and product availability.

The focus on TB medications aligns with the high prevalence of tuberculosis in South Africa, which has one of

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — UPD LEA Glen

What products does UPD LEA Glen import from India?

UPD LEA Glen imports 2 pharmaceutical products across 1 categories. Top imports: Ethambutol ($650.0K), Pyrazinamide ($650.0K).

Who supplies pharmaceuticals to UPD LEA Glen from India?

UPD LEA Glen sources from 10 verified Indian suppliers. The primary supplier is Lupin Limited (67.5% of imports, $13.8M).

What is UPD LEA Glen's total pharmaceutical import value?

UPD LEA Glen's total pharmaceutical import value from India is $1.3M, based on 26 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does UPD LEA Glen focus on?

UPD LEA Glen imports across 1 categories. The largest: Tuberculosis Medications (100.0%).

Get Full UPD LEA Glen Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.